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Background: The use of systematic review methods are widely recognized to be essential in the development of
recommendations in clinical practice guidelines to prove their trustworthiness. The objective of this study was to
assess the use of systematic search methods by authors of guidelines published in the oncology field.
Methods: We analyzed 590 guidance documents identified in PubMed, NGC, GIN and web sites for guidelines in
2009–2015 in oncology. The main outcome measure used was incidence of guidance documents supported by a
systematic search of the literature. In addition to descriptive analyses, logistic regression was used to evaluate if
adequate search methods were explained by guideline characteristics.
Results: Of 590 guidance documents included in the study, 305 (51.7%) declared the use of systematic search
methods but only 168 (28.5%) applied methods meeting minimum standards for quality and provided sufficient
details to allow classification. 164 (27.8%) guidance documents did not report any use of literature evaluation.
Guidance documents produced by a Government Agency in North America (OR 2.16, 95% CI 1.16–4.17) and those
with a focused scope (OR 2.35, 95% CI 0.97–5.56) were positively associated with the use of systematic search
methods. We found no association between the year of publication and use of systematic search methods.
Conclusions: A relatively small number of guidance documents was informed by scientific evidence identified
through adequate systematic search methods. We observed substantial room for improvement of applied methods
and reporting, especially in documents with a broad focus, or those produced by professional societies or
independent expert panels in other continents than North America.
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Clinical practice guidelines (CPGs) are defined by Institute
of Medicine (IOM) as statements that include recommen-
dation intended to optimize patient care. They are in-
formed by a systematic review of evidence and assessment
of the benefit and harms of alternative care options [1].
This definition emphasizes the fact that clinical recom-
mendations need to be based on the best available evi-
dence evaluated through a systematic review of the
medical literature.© The Author(s). 2019 Open Access This artic
International License (http://creativecommons
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Full list of author information is available at the end of the articleAccording to the Cochrane collaboration handbook “A
systematic review attempts to collate all empirical evi-
dence that fits pre-specified eligibility criteria in order to
answer a specific research question. It uses explicit, sys-
tematic methods that are selected with a view to minimiz-
ing bias, thus providing more reliable findings from which
conclusions can be drawn and decisions made.” [2–4].
Similarly, the IOM and the Guidelines International
Network (GIN) recommend that guideline developers
use systematic review methods to identify and evaluate
evidence related to the guideline topic [1, 5]. Selective
assessment and unstructured appraisal of the literature
may lead to recommendations that promote suboptimal
or even harmful care [6]. Therefore, clinicians should
consider whether recommendations in a guideline arele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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the guideline has been prepared according to proper
methodological requirements.
A well-defined, transparent and reproducible search
strategy along with grey literature searches and selection
criteria to include evidence should be the starting point
to achieve evidence-based CPGs [7].
The quality of practice guidelines has already been a
source of concern in the past. In a previous overview
Grilli and colleagues found that 87% of 431 analyzed
guidelines did not report any information on the system-
atic search, although the proportion of guidelines report-
ing some form of search increased over time (2% in
1988–91 to 18% in 1996–98) [8].
The landscape for CPGs has significantly changed
in the last two decades since the National Guideline
Clearinghouse [9] was launched, the GIN Inter-
national Guidelines Network [10] was established,
and the Appraisal of Guidelines for Research and
Evaluation (AGREE) consortium [11] and the Grad-
ing of Recommendations Assessment, Development
and Evaluation (GRADE) working group [12] started
their activities. GRADE methodology has impacted
on CPGs definition and grading the quality of evi-
dence, while quality and reporting for CPGs are
widely evaluated by AGREE II tool. Nonewithstand-
ing, we assisted to a world-wide proliferation of
CPGs produced with different methods, and pub-
lished in different reporting modalities by different
panels.
Considering that systematic review of published evi-
dence is an essential component in the methodo-
logical process of CPGs production, understanding
how search strategies are used by Guideline Develop-
ment Panels (GDPs) is important. Recently, three arti-
cles on reporting CPGs were published, but none of
them assessed whether GDPs provided sufficient de-
tails to conclude that systematic searches were indeed
performed [7, 13, 14].
In fact, from a methodological point of view a guide-
line is classified as Clinical Practice Guideline when it
provides sufficient details to demonstrate that a system-
atic search and other systematic review steps were per-
formed. In absence of any description of the search, or if
the described strategy did not meet a set of minimum
criteria, the document would be best referred to as
“guidance document” [15].
The objective of this study, that is collateral to a na-
tional project aiming at synthesizing recommendations
on traditional circulating tumor markers in solid tumors
[16–18], was to assess the use of systematic search
methods in CPGs in oncological field as a test context
framework, and to determine which context variables
were associated with adequate use.Methods
Search strategy
A systematic literature search for existing guidelines in
oncology published in English or Italian was undertaken
using PubMed, National Guideline Clearinghouse, GIN
Library databases and websites of 11 organizations and
61 Italian scientific societies producing CPGs. The
search strategy was built with keywords related to cancer
and guidelines. Full details are described in Add-
itional file 1. Selection was independently performed by
3 examiners on the basis of the titles and abstracts of
the identified records. A record was default included
when at least 2 out of 3 examiners opted for inclusion.
When only one examiner opted for inclusion, disagree-
ment was resolved by discussion.
Full-text reports were retrieved for the potentially eli-
gible documents. Every reasonable effort was made to lo-
cate related reports to included guidance documents
online, that could provide additional information regard-
ing the methodology used to generate the CPG
recommendations.
Selection criteria
Any document containing information and recommen-
dations pertaining to diagnosis, work-up, management,
treatment or follow-up of tumors on adult population
was included. Moreover, documents had to meet all of
the following eligibility criteria to be included:
 contain recommendations intended to optimize
patient care and assist physicians, other practitioners
and patients, to make decisions about appropriate
health care for specific clinical circumstances;
 be produced under the auspices of, or endorsed by,
government agencies or health care organizations,
medical specialty associations or relevant
professional societies;
 be produced, reviewed, reassessed for validity or
updated between 2009 and 2015;
 being accessible in the public domain.
The following documents were excluded from the
analysis:
 guidelines concerning malignancies in which
traditional circulating tumor markers are not
considered (e.g. brain tumors, soft tissue tumors,
musculoskeletal tumors, non-melanoma skin can-
cers, hematological malignancies, hereditary/familial
cancers);
 guidelines concerning malignancies in which
traditional circulating tumor markers have no role
in risk assessment or in the management
(documents focusing only on screening, prevention,
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subgroups of patients, such as pregnant women,
children, adolescents, homeless people);
 health technology assessment reports, systematic
review and network meta-analyses;
 narrative reviews and comments or editorials
accompanying the guidelines;
 guidelines developed and issued by an individual(s)
not officially sponsored or supported by one of the
organization types cited above.
Some reports were identified as multiple reports be-
longing to an unique guidance document if they were ei-
ther ordered by the same organization/producer or
produced during the same consensus meeting or if they
were explicitly cited in the main guidance document. In
these cases all the identified multiple reports were in-
cluded to allow for a full appreciation of the guideline
but they count as one document in our logistic analyses.
When the same guideline developer or GDP published
guidance documents in different formats (summarized,
abridged, or full version), or published in different jour-
nals or websites, we included the most recent un-
abridged version as main report.
Data extraction
For each included guidance document, we collected the
following characteristics.
 year of publication;
 scope of guidelines: broad (Multi-aspect, e.g. from
diagnosis to metastatic disease management) or
focused (centered on a specific clinical question or
topic);
 type of organization/producer classified as
Professional/Specialist Society, Government Agency,
Independent Expert Panel, Other (Not-for-profit
Organization, For-profit Organization, International
Agency-i.e. WHO, Academic Institution);
 continent (considering the “seven-continent model”)
classified as North America (United States, Canada),
South America, Europe, Asia, Oceania, Africa,
International (GDP members or producers from two
or more continents);
 cancer type.
Detailed information on degree of traceability of pub-
lished evidence in the produced recommendations was
collected following this pattern (Fig. 1):
 Was the production of recommendations based on
any literature analysis?
 If yes, did the GDP declare a systematic search of
literature? A very inclusive approach was used, forexample, it was considered sufficient that the
general review process was described as
“comprehensive” or “extensive”, or that a database
search was done.
 If yes, did the GDP report details on the systematic
review methods (i.e. biomedical database and/or web
site search, keywords)?
A systematic search strategy was considered sufficient
and appropriate when all of the following three criteria
were met:
 explicit reporting of the use of at least one
biomedical database (e.g. MEDLINE);
 use of at least one additional source to retrieve
citations, such as another biomedical database,
screening of reference lists of included reports,
personal communication with investigators or
organizations;
 explicit description of the search terms used in
bibliographic search(es).
When above criteria were met, the guidance document
was classified as being informed by a systematic search
method (SR). These criteria were inspired by the de-
scriptions of Oxman and Guyatt in 1988 [19, 20]. A very
similar approach was used by NICE in 2004 [21].
Two reviewers (CT, MC) have independently evaluated
the guidance documents classifying them as documents:
 without explicit description of the use of literature
analysis (noLA);
 with literature analysis but without reference to the
use of systematic search methods (noSR);
 described to be based on one or more systematic
reviews, not providing details to demonstrate it
(SRnoDT);
 described to be based on one or more systematic
reviews, with a search strategy not meeting our
quality criteria (SRinsDT);
 described to be based on one or more systematic
reviews, with a search strategy meeting our quality
criteria (SR).
Any disagreement on the classification process was re-
solved by discussion or involvement of a third examiner
(AR) until consensus was reached.Data analysis
Categorical variables were described as frequencies and
percentages, considering the unit of analysis being the
individual guidance document. Descriptive analyses were
performed on all guidelines categories.
Fig. 1 Guidance documents classification algorithm
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tics and the type of literature evaluation was examined
by univariate regression model analysis in two models.
Model 1 included the whole sample of guidelines, in
order to compare documents declaring the use of sys-
tematic search methods (SR; SRinsDT; SRnoDT) with
documents without declaration of systematic review or a
literature analysis (noSR and noLA). Model 2 was re-
stricted to documents declaring the use of systematic
search methods. In this model, we evaluated the associ-
ation between guideline characteristics and the use of
adequate search methods. The dependent variable in
these logistic regression analyses was dichotomized in
sufficient and appropriate (SR, as defined above) vs. less
rigorous systematic search strategy (SRinsDT &
SRnoDT). We presented the results of Model 2 into twoseparate analyses, (SR vs SRinsDT) and (SR vs SRnoDT),
respectively.
Documents produced from and published by the same
organization, were included as a clustering variable in
the regression analyses to obtain robust variances.
The independent variables evaluated in both models
concerned:
a. year of publication as continuous variable;
b. type of organization/producer as categorical
variable, defining Government Agency as the
contrast;
c. scope as categorical variable, defining Broad as the
contrast;
d. continent as categorical variable, defining
International as the contrast.
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variables in a multivariable model to assess the predic-
tors of the use of well conducted/reported systematic
search methods.
Results are reported as odds ratios (ORs) with 95%
CIs. Analyses were performed using SAS (Statistical
Analysis System, SAS Institute Inc., Cary, NC, USA, Ver-
sion 9.2) software. All tests were two-sided and P < 0.05
was used to determine statistical significance.
The study involved no human participants and re-
quired no ethical approval.Results
Selection of guidelines
Overall, of 6330 titles and abstract retrieved from the da-
tabases and websites searches, 1065 reports were identi-
fied as potentially eligible. Four hundred seventy-five
were excluded after screening of the full-text. A final set
of 590 guidance documents was identified. Full list is re-
ported in Additional file 2. Figure 2 shows a modified
PRISMA flow diagram [22].Fig. 2 PRISMA 2009 Flow Diagram (modified)Guideline characteristics
Table 1 shows the characteristics of the included guid-
ance documents. Overall, the number of guidelines in-
creased during the years and their scope was focused in
346/590 (58.6%). Most of the documents were developed
by Professional or Specialist Societies (378/590, 64.1%),
followed by Government Agencies (108/590, 18.3%) and
by Independent Expert Panels (80/590, 13.6%). They
were published predominantly in North America (247/
590, 41.9%) and Europe (222/590, 37.6%). No document
published in Africa was identified. Guidelines were re-
lated to all tumor types, with the number of identified
documents ranging from 2 documents for pleural neo-
plasm to 68 documents for prostatic cancer.
One hundred sixty four (27.8%) documents did not de-
clare any literature analysis, while 72.2% (n = 426) based
the production of recommendations on literature evalu-
ation. Of these 121 (28.4%) did not report a systematic
literature review.
In 305 guidelines the GDP declared to have performed
a systematic search of the literature. In this subgroup,
168/305 (55.1%) met our quality standards, 111/305
Table 1 Characteristics of 590 guidance documents by type of search methods
Characteristic All
(n = 590)
SRb
(n = 168)
SRinsDTc
(n = 111)
SRnoDTd
(n = 26)
noSRe
(n = 121)
noLAf
(n = 164)
Year of validity
2009 41 (6.9%) 4 (3.6%) 2 (7.7%) 7 (5.8%) 16 (9.8%) 12 (7.1%)
2010 44 (7.5%) 6 (5.4%) 4 (15.4%) 9 (7.4%) 13 (7.9%) 12 (7.1%)
2011 69 (11.7%) 17 (15.3%) 3 (11.5%) 8 (6.6%) 26 (15.8%) 15 (8.9%)
2012 95 (16.1%) 22 (19.8%) 6 (23.1%) 22 (18.2%) 16 (9.8%) 29 (17.3%)
2013 115 (19.5%) 27 (24.3%) 4 (15.4%) 28 (23.1%) 22 (13.4%) 34 (20.3%)
2014 141 (23.9%) 20 (18.1%) 4 (15.4%) 30 (24.8%) 40 (24.4%) 47 (28.0%)
2015a 85 (14.4%) 15 (13.5%) 3 (11.5%) 17 (14.1%) 31 (18.9%) 19 (11.3%)
Scope
Broad 244 (41.4%) 29 (26.1%) 15 (57.7%) 74 (61.2%) 77 (47.0%) 49 (29.2%)
Focused 346 (58.6%) 82 (73.9%) 11 (42.3%) 47 (38.8%) 87 (53.0%) 119 (70.8%)
Producer
Government
Agency
108 (18.3%) 10 (9.0%) 0 3 (2.5%) 6 (3.7%) 89 (53.0%)
Independent
Expert Panel
80 (13.5%) 11 (9.9%) 5 (19.2%) 27 (22.3%) 25 (15.2%) 12 (7.0%)
Professional /
Specialist Society
378 (64.1%) 83 (74.8%) 16 (61.6%) 88 (72.7%) 125 (76.2%) 66 (39.3%)
Other 24 (4.1%) 7 (6.3%) 5 (19.2%) 3 (2.5%) 8 (4.9%) 1 (0.6%)
Continent
Asia 52 (8.8%) 10 (9.0%) 6 (23.1%) 7 (5.8%) 24 (14.6%) 5 (2.9%)
Oceania 14 (2.4%) 3 (2.7%) 1 (3.8%) 3 (2.5%) 2 (1.2%) 5 (2.9%)
Europe 222 (37.6%) 18 (16.2%) 10 (38.5%) 78 (64.4%) 76 (46.3%) 40 (23.8%)
North America 247 (41.9%) 71 (64.0%) 3 (11.5%) 19 (15.7%) 45 (27.5%) 109 (64.9%)
South America 7 (1.2%) 2 (1.8%) 0 3 (2.5%) 1 (0.6%) 1 (0.6%)
International 48 (8.1%) 7 (6.3%) 6 (23.1%) 11 (9.1%) 16 (9.8%) 8 (4.9%)
Neoplasm
Anal cancer 9 (1.5%) 3 (2.7%) 0 1 (0.8%) 2 (1.2%) 3 (1.8%)
Biliary cancer 12 (2.0%) 3 (2.7%) 6 (23.1%) 2 (1.7%) 1 (0.6%) 0
Bladder cancer 27 (4.6%) 9 (8.1%) 2 (7.8%) 4 (3.3%) 5 (3.1%) 7 (4.2%)
Breast cancer 45 (7.6%) 8 (7.2%) 3 (11.5%) 5 (4.1%) 14 (8.5%) 15 (8.9%)
Cervical cancer 18 (3.0%) 4 (3.6%) 2 (7.8%) 3 (2.5%) 4 (2.4%) 5 (3.0%)
Colorectal cancer 52 (8.8%) 12 (10.8%) 1 (3.8%) 12 (9.9%) 14 (8.5%) 13 (7.7%)
Endometrial cancer 17 (2.9%) 5 (4.5%) 0 3 (2.5%) 3 (1.8%) 6 (3.5%)
Esophageal cancer 15 (2.5%) 2 (1.8%) 0 4 (3.3%) 3 (1.8%) 6 (3.5%)
Gastric cancer 18 (3.1%) 2 (1.8%) 0 4 (3.3%) 9 (5.5%) 3 (1.8%)
Germ cell tumor 3 (0.5%) 0 0 1 (0.8%) 1 (0.6%) 1 (0.6%)
Head and neck cancer 16 (2.7%) 0 1 (3.8%) 5 (4.1%) 7 (4.3%) 3 (1.8%)
Hepatocellular carcinoma 29 (4.9%) 4 (3.6%) 2 (7.8%) 7 (5.8%) 10 (6.1%) 6 (3.5%)
Incidentaloma 5 (0.9%) 2 (1.8%) 0 0 2 (1.2%) 1 (0.6%)
Lung cancer 55 (9.3%) 10 (9.1%) 1 (3.8%) 7 (5.8%) 12 (7.3%) 25 (14.9%)
Melanoma 20 (3.4%) 0 1 (3.8%) 4 (3.3%) 8 (4.9%) 7 (4.2%)
Mesothelioma 8 (1.4%) 0 1 (3.8%) 1 (0.8%) 3 (1.8%) 3 (1.8%)
Metastatic ab initio 4 (0.7%) 4 (3.6%) 0 0 0 0
NETs 23 (3.9%) 3 (2.7%) 1 (3.8%) 9 (7.5%) 7 (4.3%) 3 (1.8%)
Ovarian cancer 28 (4.8%) 4 (3.6%) 1 (3.8%) 7 (5.8%) 7 (4.3%) 9 (5.4%)
Pancreatic cancer 17 (2.9%) 2 (1.8%) 1 (3.8%) 3 (2.5%) 6 (3.7%) 5 (3.0%)
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Table 1 Characteristics of 590 guidance documents by type of search methods (Continued)
Characteristic All
(n = 590)
SRb
(n = 168)
SRinsDTc
(n = 111)
SRnoDTd
(n = 26)
noSRe
(n = 121)
noLAf
(n = 164)
Penile cancer 5 (0.9%) 2 (1.8%) 0 1 (0.8%) 1 (0.6%) 1 (0.6%)
Pleural disease 2 (0.3%) 0 0 0 0 2 (1.2%)
Prostatic cancer 68 (11.5%) 15 (13.5%) 2 (7.8%) 12 (9.9%) 18 (11.0%) 21 (12.5%)
Renal cancer 23 (3.9%) 5 (4.5%) 0 6 (5.0%) 6 (3.7%) 6 (3.5%)
Testicular cancer 14 (2.4%) 1 (0.9%) 1 (3.8%) 5 (4.1%) 3 (1.8%) 4 (2.4%)
Thyroid cancer 25 (4.2%) 7 (6.3%) 0 6 (5.0%) 5 (3.1%) 7 (4.2%)
Unknown primary site 4 (0.7%) 0 0 1 (0.8%) 2 (1.2%) 1 (0.6%)
Multiple cancer 25 (4.2%) 4 (3.6%) 0 8 (6.6%) 11 (6.7%) 2 (1.2%)
Other 3 (0.5%) 0 0 0 0 3 (1.8%)
aFrom January, 1st to July, 15th
bSR = systematic search methods meeting our quality criteria; cSRinsDT = described systematic search methods did not meet our quality criteria;
dSRnoDT = use of systematic search described, but no details provided; enoSR = literature analysis described, but not as systematic; fnoLA = no reference
to any type of literature analysis
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criteria out of three were met) and 26/305 (8.5%) did
not provide any detail on the search methods used.
Among the 111 guidance documents performing a sys-
tematic search not meeting our quality standards, 12/
111 (10.8%) reported the biomedical database search
only, 36/111 (32.4%) reported details on biomedical
database search and other sources, while 60/111 (54.1%)
reported details on biomedical database search and key-
words. Two guidance documents reported only the key-
words and 1 reported keywords and other sources but
not the biomedical database searched.
Regression analyses
Results are reported in Table 2
Model 1
The univariate models including all 590 guidance docu-
ments. Despite the increased number of guidelines pro-
duced over the years, the ratio between documents
declaring and those not declaring the use of systematic
search methods remained unchanged (OR 0.98, 95% CI
0.91–1.06). No trend was detected over the year (p for
trend = 0.732).
The probability of declaring a systematic search
method was strongly influenced by the scope of the
guidance document. Documents with a focused scope
were more likely to report the use of systematic search
methods (OR 2.57, 95% CI 1.47–4.55).
Taking government agencies as a reference, all docu-
ments developed by other guideline producers were less
likely to declare the use a systematic search. Guidance
documents produced by an independent expert panel
have the highest probability of not declaring any system-
atic search (OR 0.05, 95% CI 0.02–0.10).
The only continent associated with a significant higher
uptake of systematic search methods was North Americawith an OR of 3.68 (95% CI 2.22–5.88). This result was
confirmed when considering USA and Canada as dis-
tinct nationalities (data not shown).Model 2
The univariate models included guidance documents ex-
plicitly mentioning the use of systematic searches (n =
305). Guidelines having a focused scope and being pro-
duced in North America more often met our quality cri-
teria for adequate search methods (OR 3.33; 95% CI
1.20–9.12 and OR 27.25; 95% CI 6.01–123.48 respect-
ively). When we used documents meeting some but not
all of our quality criteria as comparator, the evidence
was less conclusive (OR 0.86; 95% CI 0.56–1.32 and OR
1.34; 95% CI 0.53–3.11 respectively). Producers other
than government agency were less likely to meet all or
part of our quality criteria for adequate search strategies.
Table 3 presents results from the multivariable regres-
sion analyses, confirming those from univariate models.
A systematic search was more likely to be declared if
documents were produced in North America, by a gov-
ernment agency and with a focused scope. In model 2,
using documents not explaining search methods as com-
parator, the multivariate analysis showed that documents
produced in North America, by a Government agency,
with a focused scope were more likely to use sufficient
methods. Using documents meeting some but not all of
the quality criteria as comparator, we found no statisti-
cally significant associations, except for non-
governmental bodies that remain associated with lower
probabilities of using sufficient search methods.Discussion
In the present study we analyzed guidance documents
published over a 5 year period in oncology to evaluate
the use of systematic searches, the adequateness of these
Table 2 Results of the univariate logistic regression analyses
Independent variable Reference
category
Effect Odds Ratio (95% CI)
Model 1 – n = 590
(SR, SRinsDT, SRnoDT vs noSR,
noLA)a
Odds Ratio (95%
CI)
Model 2 – n = 305
(SR vs SRinsDT)a
Odds Ratio (95%
CI)
Model 2 – n = 305
(SR vs SRnoDT)a
Year of validity
(continuous
variable)
– Year of validity 0.98 (0.91–1.06) 1.01 (0.90–1.13) 1.17 (0.95–1.45)
Year of validity 2009 2010 1.28 (0.67–2.43) 1.50 (0.47–4.76) 2.00 (0.40–10.00)
2011 1.32 (0.57–3.03) 3.40 (0.99–11.73) 1.20 (0.32–4.58)
2012 1.92 (0.12–3.23) 2.28 (0.85–6.09) 1.24 (0.23–6.75)
2013 1.66 (1.02–2.70) 2.38 (0.79–7.22) 0.71 (0.16–3.17)
2014 1.30 (0.72–2.32) 1.28 (0.47–3.48) 0.51 (0.21–1.24)
2015 0.99 (0.52–1.89) 2.37 (0.67–8.36) 0.95 (0.11–8.36)
Scope Broad Focused 2.57 (1.47–4.55) 0.86 (0.56–1.32) 3.33 (1.20–9.12)
Producer Government
Agency
Independent expert panel 0.05 (0.02–0.10) 0.12 (0.04–0.38) 0.02 (0.00–0.11)
Professional or specialist
society
0.07 (0.03–0.15) 0.09 (0.05–0.16) 0.03 (0.00–0.15)
Other 0.11 (0.04–0.39) 0.02 (0.01–0.14) 0.01 (0.00–0.02)
Continent International Asia 0.87 (0.43–1.75) 0.44 (0.18–1.05) 0.63 (0.16–2.46)
Oceania 2.31 (0.71–7.14) 1.46 (0.37–7.45) 3.75 (0.34–40.84)
Europe 0.57 (0.31–1.03) 1.94 (0.76–6.03) 3.00 (0.97–9.33)
North America 3.68 (2.22–5.88) 1.34 (0.53–3.11) 27.25 (6.01–
123.48)
South America 0.96 (0.25–3.70) 0.33 (0.01–5.57) 0.15 (0.01 - ∞)
ORs larger than 1 refer to increased use of systematic search methods in model 1 and increased use of search methods meeting our quality criteria in model 2
aAbbreviations are explained in Table 1
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ated with adequate use.
We found that, although a majority of guidance docu-
ments is informed by literature analyses, only a minority
met pre-defined criteria for systematic search methods.
Still about a quarter of guidance documents did not per-
form a literature analysis at all to produce recommenda-
tions. Moreover, we found no evidence that the use of
systematic search methods or its adequateness improved
over time since 2009 to 2015. Guidance documents with
a focused scope produced by governmental bodies, espe-
cially in North America were most likely to use sufficient
search methods.
The formation of a guideline panel with strong clinical
and methodological background is paramount for devel-
oping and using guidelines. Any guideline being consid-
ered for guiding clinical practice, endorsement or
adaptation should be informed by appropriate and up-to-
date systematic reviews of the literature. The adequateness
of a search strategy is determined by several factors and in
this study, we only stipulated three minimum criteria that
a search strategy should meet: searching at least one bib-
liographic database, searching at least one additional
source and reporting keywords. We found that the vast
majority (7 out of 10) of guidance documents did notmeet this limited set of quality criteria. Within the set de-
claring the use of systematic search methods, still 4 out of
10 did not meet our criteria so that we observed room for
improvement in both the use and reporting of adequate
search strategies.
Our regression analyses showed strong positive associ-
ations between declared use of systematic search
methods and guideline production by government agen-
cies and in North America. These results are possibly
due to involvement and funding from public institutions
and perhaps the strong uptake of evidence based
methods in this area. On the other hand, the positive as-
sociations found between declared use of systematic
search methods and guideline production in North
America seems not due to the fact that both the USA
and Canada are high income countries. In fact, guidance
documents from two other continents (Europe and
Oceania) are all produced in high income countries and
551 out of 590 examined guidance documents are pro-
duced by high income countries. Despite the availability
of guidance tools for guidelines development and assess-
ment (GRADE, AGREE, GIN and IOM standards) being
progressively disseminated in the past decade, we did
not detect an improved uptake of literature analyses or
systematic search methods in the past 5 year.
Table 3 Results of the multivariable regression analyses
Independent
variable
Reference category Effect Odds Ratio (95% CI)
Model 1 – n = 590
(SR, SRinsDT, SRnoDT vs noSR,
noLA)a
Odds Ratio (95%
CI)
Model 2 – n = 305
(SR vs SRinsDT)a
Odds Ratio (95%
CI)
Model 2 – n = 305
(SR vs SRnoDT)a
Scope
Year of validity 2009 2010 1.59 (0.58–4.35)
2011 2.04 (0.69–5.88)
2012 2.70 (1.23–5.88)
2013 1.92 (0.89–4.35)
2014 1.45 (0.54–3.85)
2015 1.67 (0.56–5.00)
Broad Focused 2.35 (0.97–5.56) 1.04 (0.49–2.20) 3.48 (0.89–13.61)
Producer Government
Agency
Independent expert panel 0.05 (0.03–0.10) 0.10 (0.03–0.31) 0.13 (0.00–0.96)
Professional or specialist
society
0.09 (0.04–0.16) 0.08 (0.04–0.15) 0.07 (0.00–0.33)
Other 0.13 (0.04–0.42) 0.01 (0.00–0.05) 0.01 (0.00–0.03)
Continent International Asia 0.90 (0.35–2.86) 0.40 (0.11–1.53) 0.85 (0.16–4.53)
Oceania 1.00 (0.34–4.17) 2.24 (0.12–40.82) 6.11 (0.51-∞)
Europe 0.50 (0.23–1.05) 1.15 (0.40–3.29) 2.89 (0.49–17.09)
North America 2.16 (1.16–4.17) 0.50 (0.19–1.29) 17.43 (2.28–
133.44)
South America 1.30 (0.23–10) 0.37 (0.02–6.29) 0.44 (0.02-∞)
ORs larger than 1 refer to increased use of systematic search methods in model 1 and increased use of search methods meeting our quality criteria in model 2
aAbbreviations are explained in Table 1
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progressively assumes systematic searches to be “obvi-
ously done” in comprehensive guidance documents that
were produced over the past years. The more recent
reporting tools for practice guidelines in health care can
be taken as an example [7, 13]. The RIGHT Working
Group developed a checklist that includes 22 items con-
sidered essential for proper reporting of CPGs; as con-
cerns evidence, the items 11a and 11b query how
systematic reviews were done, not if they were done.
One could reason that a document omitting descriptions
of a systematic review process is a guidance document
rather than a CPG, but still our findings are alarming.
Guidance documents not meeting basic search require-
ments are used to drive appropriate clinical decisions
and second, in spite of intentions and advice of GDPs,
guidance documents are more and more commonly used
as formal documents in specific fields such as health pol-
icies and legal litigations, without adequate implementa-
tion processes in clinical practice.
Every GDP can choose a reporting format based on
their specific audience [13]. Taking lung cancer as an
example, the National Institute for Health and Care
Excellence reported all clinical questions in a unique
document [23]. Conversely, the Cancer Care Ontario [24]
produced separate guidelines for every clinical condition
(diagnosis, initial work-up, therapy monitoring, etc)whereas the American College of Chest Physicians pub-
lished different reports in an unique journal supplemen-
tary number [25]. It was therefore challenging to classify
multiple reports in order to fit with the clinical questions
fixed in the present study for individual malignancies and
for specific clinical conditions (diagnosis, initial work-up,
therapy monitoring, etc). The adoption of different classi-
fications of multiple reports leads to different counts of
examined documents.
Strengths and limitations of this study
A strength of the present study was the use of a dupli-
cate and independent processes throughout the project
as well as the use of systematic and transparent method
in searching, screening and collecting data. Moreover,
we reported on a representative sample of guidance doc-
uments in oncology, without restricting to the type of
clinical questions addressed.
Our study also presents some limitations. Regarding
applicability, although oncology is a crucial health sector,
it remains to be investigated if our results can be trans-
ferred to other healthcare areas. In addition, as the ma-
jority of the identified guidelines were developed in
Europe and North America, both high-income countries,
our sample may not be representative to middle or low
income countries. Our selection may be biased by the
English / Italian language limit that was imposed in the
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searched. We however reason that it is unlikely that our
findings would be more favorable if our search methods
would have been broader. To clarify, Italian national
guidelines were included in the present study because it
was branded from a national project in Italy aiming at
extensively evaluating and synthesizing recommenda-
tions on tumor markers [16–18]. However, the number
of Italian guidelines identified pose a small percentage of
both the European and the total guidelines evaluated
(n = 24/222, 11%; n = 24/590, 4%, respectively). Poor
reporting of search strategies may have led to misclassifi-
cations. This type of bias occurs in any methodological
assessment of any type of research, but we attempted to
avoid misclassifications as much as possible by actively
searching for multiple reports to identified guidance
documents that might contain additional information on
search methods. Lastly, although a relatively large set of
documents was identified, the number of documents de-
claring the use of systematic search methods was rather
small. Consequently, the evaluation of adequateness of
applied methods resulted in typically wide confidence in-
tervals around the summary estimates so that the magni-
tude of associations are uncertain.
In context with previous studies and policy implications
In the present study we confirm and expand similar find-
ings from other studies in more restricted areas. Grilli
et al. reported in 2000 that the majority of documents
published as CPGs do not provide evidence of the use of
systematic review methods [8]. In 2008, Somerfield
showed that few professional organizations rely on sys-
tematic reviews as the basis for oncology guidelines [26].
Reames et al., who evaluated oncology guidelines for can-
cer type with high mortality, noted a poor compliance
with IOM standard’s systematic review criteria [27].
Findings of the present study indicate two issues to be
considered in future guideline preparation: the first issue
concerns the policy of guideline development, which is
best improved at an organizational level and at the level
of steering groups which have roles and responsibilities
in managing guideline production; the second is focusing
on improving methodology and/or reporting, which is
best addressed in the GDPs which include both clinical
experts and methodologists.
Conclusion
In this systematic review of guidance documents in the
field of oncology, we found that there still is substantial
room for improvement of the uptake of adequate system-
atic search methods in the development of guidelines.
Only a relatively small proportion of guidance documents
was informed by scientific evidence identified through
adequate systematic search methods. Best strategies toobtain improvement will vary across settings and conti-
nents but may involve educational interventions to
sensitize CPGs producers to improve quality of methods
and reporting but also governmental interventions to
promote adequate methods with a call to scientific organi-
zations to reduce the number of documents that are based
on expert opinions without systematically evaluating the
scientific literature.
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